Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/04 10:01:27 pm
54.81 USD   -0.49%
10:20p Business events scheduled for Thursday
02:09p MERCK : to Present at the Deutsche Bank 41st Annual Health Care Conf..
05/03DJGilead Seeks to Tame Merck Case -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
10:20p Business events scheduled for Thursday
02:09p MERCK : to Present at the Deutsche Bank 41st Annual Health Care Conference
05/03DJGilead Seeks to Tame Merck Case -- WSJ
05/02DJJudge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney..
05/02DJJudge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney..
05/02DJJudge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney..
05/02DJJudge Allows More Evidence in Gilead-Merck Patent Dispute
04/30 MERCK : Quick hits
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue
04/28 MERCK : Montana State offering live stream of vaccine expert panel
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials